GDTC — CytoMed Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $11.83m
- $10.80m
- SG$0.32m
Annual income statement for CytoMed Therapeutics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.07 | 0.324 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.309 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.05 | 3.13 | 4.13 | 2.59 | 4.32 |
| Operating Profit | -2.05 | -3.13 | -4.13 | -2.52 | -4 |
| Net Income Before Taxes | -2.05 | -3.13 | -4.13 | -2.52 | -4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.05 | -3.13 | -4.13 | -2.52 | -4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.05 | -3.13 | -4.13 | -2.52 | -3.98 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.05 | -3.13 | -4.13 | -2.52 | -3.98 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.188 | -0.272 | -0.389 | -0.218 | -0.341 |
| Dividends per Share |